ENYO Pharma selected in the FrenchTech 120

Published on 22/01/2020

ENYO Pharma is proud to be part of the FrenchTech 120 with such promising companies. It is a strong recognition from the French State.

Read next in 'Latest news'

• La Phase 2
• Enrollment completed for our Phase 2 clinical trial in Alport syndrome
• The first patient dosed in the Phase 2 ALPESTRIA-1 clinical study of Vonafexor for Alport syndrome
• The Phase 2 ALPESTRIA-1 clinical study has started with Vonafexor on Alport syndrome
• Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)